General Hospital Psychiatry
Volume 26, Issue 3 , Pages 245-247 , May 2004

Worsening of psychosis or topiramate-induced adverse event?

  • Harpreet S. Duggal, M.D., D.P.M.

      Affiliations

    • Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
    • ,
  • Ira Singh, M.B.B.S.

      Affiliations

    • Pt. BDS Postgraduate, Institute of Medical Sciences, Rohtak, Haryana, India

References 

  1. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry. 2003;64(Suppl 8):S9–S14
  2. Davanzo P, Cantwell E, Kleiner J, et al.  Cognitive changes during topiramate therapy. J Am Acad Child Adolesc Psychiatry. 2001;40:262–263
  3. Physicians' desk reference. Montvale (NJ): Thomson PDR; 2003;
  4. Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure 1999;8:235–7
  5. Verhoeven WM, Boermans JA, van der Heijden FM, Tuinier S. Psychosis following treatment with topiramate. Ned Tijdschr Geneeskd. 2003;147:2093–2095
  6. Kanner AM, Wuu J, Faught E, Tatum WO, Fix A, French JA. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav. 2003;4:548–552
  7. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol. 2002;449:121–125

PII: S0163-8343(03)00147-6

doi: 10.1016/j.genhosppsych.2003.11.004

General Hospital Psychiatry
Volume 26, Issue 3 , Pages 245-247 , May 2004

Article Tools